Hemorrhoidal disease, pathology of the tissue lining the anal canal, affects approximately 10 million individuals in the US. Author Jean H. Ashburn, MD, of Wake Forest University School of Medicine and JAMA Senior Editor Karen E. Lasser, MD, MPH, discuss the current evidence on the epidemiology, pathophysiology, diagnosis, and treatment of hemorrhoidal disease.

Related Content:

• Hemorrhoidal Disease

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.

Related Content:

• Dalbavancin for Treatment of Staphylococcus aureus Bacteremia
• Management of Staphylococcus aureus Bacteremia

-----------------------------------

JAMA Editors' Summary

Prostatitis affects approximately 9.3% of men in their lifetime and includes acute and chronic bacterial infection and nonbacterial chronic prostatitis with chronic pelvic pain syndrome. Author Minh N. Pham, MD, from University of North Carolina School of Medicine discusses this and more with JAMA Deputy Editor Mary M. McDermott, MD.

Related Content:

• Prostatitis

-----------------------------------

JAMA Editors' Summary